Santen Pharmaceutical
Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.
11 past transactions
Eyevance Pharmaceuticals
Acquisition in 2020
Eyevance Pharmaceuticals LLC, established in 2017 and headquartered in Fort Worth, Texas, is a subsidiary of Santen Holdings U.S. Inc., dedicated to developing and commercializing innovative ophthalmic products. The company's portfolio includes TOBRADEX ST for treating inflammatory ocular conditions, ZERVIATE for alleviating severe eye itch, FLAREX for managing anterior segment inflammation, NATACYN for treating fungal infections, and FRESHKOTE for addressing dry eye symptoms. Eyevance focuses on addressing unmet medical needs in ophthalmology to improve patients' vision and quality of life.
Plano
Corporate Round in 2020
Plano develops a science‑based parental control application that protects children from online risks while promoting eye health. The software includes eye‑health assessment tools, myopia‑screen management, and educational events and games. By addressing the growing myopia epidemic—affecting billions worldwide—Plano helps parents monitor screen time and encourage healthier visual habits, aiming to reduce the incidence of short‑sightedness and its associated complications.
QD Laser
Series F in 2018
Founded in 2006, QD Laser specializes in manufacturing quantum dot semiconductor lasers and wafers for various applications such as communications, industrial processing, and medical imaging. Its product portfolio includes picosecond lasers for precision machining, color-specific lasers for biological sciences, laser arrays for silicon optical circuits, and broadband gain chips for ophthalmic testing. Headquartered in Kawasaki, Japan, the company serves diverse industries including telecommunications, manufacturing, medicine, and consumer products.
QD Laser
Venture Round in 2017
Founded in 2006, QD Laser specializes in manufacturing quantum dot semiconductor lasers and wafers for various applications such as communications, industrial processing, and medical imaging. Its product portfolio includes picosecond lasers for precision machining, color-specific lasers for biological sciences, laser arrays for silicon optical circuits, and broadband gain chips for ophthalmic testing. Headquartered in Kawasaki, Japan, the company serves diverse industries including telecommunications, manufacturing, medicine, and consumer products.
International Biomedical Devices
Debt Financing in 2016
International Biomedical Devices (IBMD) is an early-stage medical device company focused on ophthalmology innovations. At present, the company is leading the emerging, non-laser based, precision capsulotomy category through the development of a unique and much-needed new capsulotomy technology.
It was founded in 2013 and is based in Charleston, South Carolina.
InnFocus
Acquisition in 2016
InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma.
The company was incorporated in 2003 and is based in Miami, Florida.
InnFocus
Series C in 2015
InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma.
The company was incorporated in 2003 and is based in Miami, Florida.
RetroSense Therapeutics
Series B in 2015
RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital.
Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.
TearSolutions
Series A in 2015
TearSolutions is a biotechnology company focused on developing Lacripep, a synthetic fragment of lacritin, as a topical therapy for dry eye. The treatment uses a short, stable peptide designed to preserve the activity of a natural tear protein, restore basal tearing, and promote corneal surface healing. It targets patients with dry eye symptoms, including those associated with primary Sjögren's syndrome. The company aims to advance Lacripep through clinical development as a replacement therapy for dry eye and has pursued phase II human clinical trials. Based in Charlottesville, Virginia, TearSolutions was founded in 2013.
Clearside Biomedical
Series B in 2014
Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.
Clearside Biomedical
Series A in 2013
Clearside Biomedical is a biopharmaceutical company focused on developing treatments for serious eye diseases. It specializes in delivering drugs directly to specific compartments of the eye using its proprietary suprachoroidal injection platform, aiming to restore and preserve vision.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.